MRK
USDMerck & Company Inc. Common Stock (new)
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$82.700
Kõrge
$84.960
Madal
$82.035
Maht
6.66M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
209.5B
Tööstusharu
Drug Manufacturers - General
Riik
United States
Kauplemisstatistika
Keskmine maht
11.82M
Börs
NYQ
Valuuta
USD
52 nädala vahemik
Seotud uudised
Merck secures $700 million funding from Blackstone to develop cancer therapy
Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 million to develop an experimental cancer therapy.
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
Strategic financing to advance development of sac-TMT while Merck continues to progress its broad and expansive pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the company, through a subsidiary (Prometheus BioSciences), has reached an agreement with Dr. Falk Pharma GmbH (Falk) to
Morgan Stanley Maintains Equal-Weight on Merck & Co, Raises Price Target to $100
Morgan Stanley analyst Terence Flynn maintains Merck & Co with a Equal-Weight and raises the price target from $98 to $100.
Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
Building on the Merck Foundation's longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country The Merck Foundation announced
Merck posts higher third-quarter sales as Keytruda growth offsets drop from Gardasil
Merck & Co on Thursday posted higher third quarter revenue as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China.
Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit
Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of tariffs."
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.